Find out anti-angiogenic factor

SFlt-1 is a protein that has an antagonistic role with PlGF (which plays a role in angiogenesis). Thus sFlt-1 reduces angiogenesis and is known as antiangiogenic factor. Quantitative testing of sFlt-1 (in combination with PlGF) is often indicated in the early diagnosis and differential diagnosis of preeclampsia.

SFlt-1 was quantified by sandwich immunoassay, using electroluminescence technology. The SFlt-1 present in the sample will act as an antigen sandwiched between two antibodies: the first is a biotin-labeled sFlt-1-specific monoclonal antibody, and the second is a biotin-specific monoclonal antibody. Anti-sFlt-1 markers mark ruthenium (a luminescent substance) to form sandwich-type immune complexes. The luminescence intensity is proportional to the concentration of sFlt-1 present in the sample.

Preeclampsia is one of the obstetric complications causing serious consequences for both mother and fetus. Meanwhile, science has proven that changes in PlGF and sFlt-1 levels take place quite early before the symptoms of preeclampsia appear in pregnant women. Therefore, the quantification of sFlt-1 will help the mother diagnose preeclampsia early.

Pre-eclampsia screening for all women in the first trimester of pregnancy, to detect high-risk cases for aspirin prophylaxis. Diagnosis of preeclampsia in the second and third trimesters to provide timely treatment and intervention. Patients with suspected preeclampsia such as having high blood pressure, gestational diabetes or ultrasonography have abnormal uterine artery Doppler index, it's notch. Note: the patient should not take biotin-containing drugs at least 8 hours before the blood draw.

The technician will draw 3ml of the pregnant woman's venous blood into a tube containing anticoagulant (because this test requires the use of serum). After blood collection, the blood tube is centrifuged to separate serum. Allow specimens to be stable for 3 hours at 18-25°C, for 8 hours at 2-8°C and for 1 month at -20°C. Specimens are thawed only once and must be allowed to reach room temperature prior to analysis. To avoid evaporation, samples, standards, and quality control should be analyzed within 2 hours. Analyzer performing sample analysis: install the sFlt-1 assay program. Quality control results with the quantitative test sFlt-1 are satisfactory when the readings are not out of range and do not violate quality control laws. The person performing the sample analysis enters data about patient information and orders the test into the analyzer or network system (if any). Load the patient sample into the analyzer Command the machine to perform the analysis of the patient sample Wait for the analyzer to analyze the sample according to its protocol. When the results are available, we will review and evaluate the results, then print the report or record the results on the test sheet to return to the patient.

Quantification of anti-angiogenic factor (sFlt-1) at Vinmec Times City International Hospital is a reliable site for pregnant women.
Advantages: This technique helps prevent severe progression of preeclampsia. Reduce morbidity and mortality for both mother and fetus. Cons: The test requires to be performed on a modern machine process, requiring the technician to be precise at each stage. With the desire to provide expectant mothers with comprehensive and safe care for the mother and fetus during the pre-, during and post-partum period, Vinmec Times City International General Hospital with modern facilities Equipped with the most modern investment in Vietnam, a team of experienced medical experts, deploying all-inclusive maternity services that integrate all necessary examination and testing processes for mothers during pregnancy.